GH Research

GHRS Lead: Phase 2 8 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-15

Catalyst timeline

GH001 Ph3 startlate 2026GH001 Ph3 start, late 2026, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

mebufotenin

GH001 · GH001-TRD-201

Small Molecule

Treatment-Resistant Depression Phase 2 inhaled NCT05800860

mebufotenin

GH001

Small Molecule

Bipolar II Disorder Phase 2 inhaled NCT05839509
Postpartum Depression Phase 2 inhaled NCT05804708

mebufotenin

GH002

Small Molecule

Treatment-Resistant Depression Phase 1 intravenous

Biotech Distilled coverage (8)

2026-08-07 UPDATE: GH Research (GHRS) - The Factory Passed Inspection 🔒 Paid
2026-06-04 UPDATE: GH Research (GHRS) - The PPD Receipts Land (and They’re Loud)
2026-05-15 UPDATE: GH Research (GHRS) - The Bridging Gate Just Cleared (And a $200M ATM Joins the Party) 🔒 Paid
2026-04-29 UPDATE: GH Research (GHRS) - The Fortress Just Got Bigger (And They Used the Rip to Build It) 🔒 Paid
2026-04-27 UPDATE: GH Research (GHRS) - The White House Tailwind and a 54% Rip 🔒 Paid
2026-03-28 UPDATE: GH Research (GHRS) - Peer-Reviewed Receipts: GH001 Defies the STAR*D Paradigm 🔒 Paid
2026-03-07 UPDATE: GH Research (GHRS) - Q4/FY25 Update 🔒 Paid
2026-01-17 GH Research (GHRS): Scientific Deep Dive for GH001 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.